Recently, various forms of Churg-Strauss syndrome (CSS) have been reported in association with the use of leukotriene receptor antagonists. A 53-year-old womanwith a 5-year history of asthma associated with chronic sinusitis presented mononeuropathy, hypereosinophilia, and positive P-ANCAin October 1999. She had been treated with pranlukast (450 mg/day) and beclomethasone dipropionate (BDP) at a dose of 1,200 |ig/day which had gradually been tapered to 800 |xg/day over the previous 17 months. She was found to have CSS, and 60 mg/day of prednisolone was administered instead of pranlukast, resulting in an improvement of her symptomsand eosinophilia. Later, we confirmed that serum P-ANCAhad been positive before the pranlukast treatment, but CSS vasculitis had not appeared at that time. Wespeculated that an underlying incomplete form of CSS was being masked in this case and that the reduction of inhaled corticosteroid might have been responsible for the unmasking of CSS. (Internal Medicine 40: 432-434, 2001) 
Introduction
Churg-Strauss syndrome (CSS) is a disease characterized by generalized necrotizing vasculitis from arterioles to venules and its onset is signaled by a marked increased in peripheral blood eosinophils after being preceded for several years by chronic severe bronchial asthma. Recently, leukotriene receptor antagonist (LRA) for asthma treatment has been reported to induce an illness identical or similar to CSS (1-3). However, there have been some reports that LRAappears to offer protection against airway obstruction, thus providing the opportunity for withdrawal from corticosteroid treatment, which in turn unmasks an underlying CSS (4, 5) . Wedescribe here an asthmatic patient treated with LRA, pranlukast in whomCSS might have developed after reduction of inhaled corticosteroid.
Case Report
A 53-year-old woman having a 5-year history of asthma associated with chronic sinusitis was referred to our hospital in March1998 because of moderate asthma exacerbation. She had been treated for someunknownperiod time with inhaled corticosteroid (400-800 fig/day) and theophylline (200-400 mg/day) in conjunction with intermittent systemic corticosteroid (5-30 mg/day). Laboratory studies revealed eosinophilia of 2,960/mm3 (25.7% of her total WBCcount) and a high serum IgE level of 1,470 IU/ml (upper limit of normal is 250 IU/ ml). As shown in Fig. 1 , she was treated as having moderate asthma exacerbation with oral prednisolone (PSL; 80 mg/day), theophilline (400 mg/day), inhaled (32-agonist and pranlukast (450 mg/day). Her symptoms gradually subsided, therefore inhaled beclomethasone dipropionate (BDP) was started instead of the oral PSL. BDPwas continued at a dose of 1, 200 | Lig/day initially and gradually tapered to 800 (Xg/day administered over a 17-month period. In early October 1999, she complained of numbness in the right foot. Electromyography was notable for right median and right peroneal neuropathy consistent with mononeuritis multiplex. The eosinophil count was 13,600/mm3 (58.5% of her total WBCcount), the serum IgE level was up to 3,100 IU/ml and p-antineutrophil cytoplasmic antibody (P-ANCA) was 386 EU (normal limit is under 10 EU). Serum P-ANCAwas measured in SRLLtd laboratory ( cording to the American College of Rheumatology Criteria (6).
Wecould not perform skin biopsy because 60 mg of PSL had already been administerd in the outpatient section. Peripheral blood lymphoproliferative responses to the content of pranlukast capsule were not observed at 6 concentrations (from 288 ng/ ml to 900 |ig/ml). After pranlukast discontinuation and treatment of PSL, her symptomsand the eosinophilia were resolved within 7 days, and serum P-ANCAbecame negative. A mild neuropathy still persisted in May 2000. Later, we confirmed that serum P-ANCAhad been positive (10 EU) in the serum stored at -80°C in March 1998, but at that time CSSvasculitis had not appeared.
Discussion
This patient was found to have CSS associated with pranlukast, with positive serum P-ANCA.Only two similar CSS cases associated with pranlukast have been previously reported in the literature (7, 8) . LRAwas approved for use as asthma therapy and allowed significant reduction of systemic or high-dose inhaled corticosteroid administration, which in turn unmaskedthe underlying or unrecognized CSS(4, 5). Bili et al (9) also reported seven cases of CSSwhich were similar to those reported in association with LRAtreatment, except that none of them had been receiving LRA. However, Green and Vayonis (3) reported the occurrence of CSSin association with zafirlukast in two patients who had not received systemic steroid treatment. In previous reports and our case (1-5, 7, 8, 10) , the mean duration from the start of LRAto CSSonset in 3 LRAs were as follows; 3.2 months (n=ll, 2-8 months) with zafirlukast, 4.3 months (n=6, 2-7 months) with montelukast, and 10.6 months (n=3, 4-17 months) with pranlukast.
Pranlukast seemed to a need longer time for CSSto occur than the others, howeverthe numberof patients was too small. Further analysis of the pharmacological difference in each LRAis necessary to determine whether there are different effects in terms of unmasking the underlying and previously unrecognized (forme-fruste) CSS (1 1) among the three drugs. One of the mechanisms for the development of CSSis allergic or idiosyncratic reaction to pranlukast. However, in the present case peripheral blood lymphocyte stimulation test using pranlukast was negative. Previous reports revealed that three different molecules of LRA, zafirlukast, montelukast and pranlukast caused CSS-like diseases. And recently, cases of CSShave also been reported to the US Food and Drug Administration in association with the use of the 5-lipoxygenase inhibitor, zileuton (12) . It seems that the hypothesis of allergic or idiosyncratic reactions to pranlukast was not acceptable. Another possible mechanismis that the molecular or biological alteration of leukotriene receptor itself induced by LRAmight cause CSS. This problem should also be further examined. In general, serum P-ANCAis positive in 40-75% of patients with CSS. There has been no information about serum P-ANCAin cases of CSS associated with LRAand in particular as to whether P-ANCA had already been positive or not when LRAwas administered. In the present patient, serum PANCAhad been positive before the pranlukast treatment, but symptoms of CSS vasculitis had not yet appeared. On the other hand, Cohen et al (13) reported that prescreening for P-ANCA maynot predict the development of CSS, but that nevertheless serum P-ANCA was a useful marker to assess the disease activity of CSS when it was positive. Actually, in our case, the level of P-ANCAwas decreased in conjunction with CSSsymptoms following PSLtherapy. It was unlikely that pranlukast was directly responsible for causing CSSin our case, but rather that the subsequent reduction in inhaled corticosteroid either unmaskedor coincided with the natural course of a progressive preexisting condition of CSS.
